Blar i forfatter "Leivonen, Suvi-Katri"

Viser treff 1-3 av 3

    • Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response 

      Jernström, Sandra Johanna; Hongisto, Vesa; Leivonen, Suvi-Katri; Due, Eldri Undlien; Tadele, Dagim Shiferaw; Edgren, Henrik; Kallioniemi, Olli; Perälä, Merja; Mælandsmo, Gunhild; Sahlberg, Kristine Kleivi (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-03-21)
      Background<br> Approximately 15%–20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in treatment have been achieved after the introduction of trastuzumab and lapatinib, many patients do not benefit from these drugs. Therefore, in-depth understanding of the mechanisms ...

    • High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer 

      Normann, Lisa Svartdal; Haugen, Mads; Hongisto, Vesa; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Kristensen, Vessela N.; Tahiri, Andliena; Engebråten, Olav; Sahlberg, Guro Kristine Kleivi; Mælandsmo, Gunhild Mari (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-27)
      Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there is still a need for new therapeutic strategies as some patients respond poorly to treatment. Our aim was to identify compounds that substantially affect viability in HER2+ breast cancer cells in response to combinatorial treatment. We ...

    • MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro 

      Svartdal, Lisa Gregusson; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Haugen, Mads Haugland; Hongisto, Vesa; Kristensen, Vessela N.; Mælandsmo, Gunhild Mari; Sahlberg, Kristine Kleivi (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-05-25)
      HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We report that responsive HER2 + breast cancer cell lines had a higher number of miRNAs with altered expression after treatment with trastuzumab and lapatinib compared to poorly responsive cell ...